Figure_1.tif (359.73 kB)
Study enrollment.
figure
posted on 2012-11-06, 02:29 authored by Christina Yoon, Adithya Cattamanchi, J. Lucian Davis, William Worodria, Saskia den Boon, Nelson Kalema, Winceslaus Katagira, Sylvia Kaswabuli, Cecily Miller, Alfred Andama, Heidi Albert, Pamela Nabeta, Christen Gray, Irene Ayakaka, Laurence HuangOf 525 eligible patients, 477 (91%) were included in the study. 287 patients were enrolled during the initial baseline phase (Xpert MTB/RIF results not provided to clinicians during this validation phase) and 190 were enrolled during the implementation phase (Xpert MTB/RIF results provided to clinicians and used for patient management). Eighteen patients (nine in the baseline phase and nine in the implementation phase) died within three days of admission and were not included in survival analysis.
